Michael Mollerus

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

Davis Polk is advising Emerson Electric Co. on its $1.6 billion acquisition of Open Systems International, Inc. Emerson, headquartered in St. Louis, Missouri, is a global technology and…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Honeywell International Inc. of $2.5 billion aggregate principal amount of its 0.483…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk is advising Clarivate Plc on its approximately $6.8 billion combination with CPA Global. In the all-stock transaction, CPA Global shareholders will receive approximately 218…

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…

Davis Polk advised BRP Group, Inc. on its $175.2 million follow-on offering of 13,225,000 shares of Class A common stock, which includes 1,725,000 shares from the full exercise of the…